Skip to main content
SpringerLink
Log in

Real-world treatment patterns of venetoclax and azacytidine therapy in Japanese patients with acute myeloid leukemia

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617–629. https://doi.org/10.1056/NEJMoa2012971

    Article  CAS  PubMed  Google Scholar 

  2. Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B et al (2020) Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135(24):2137–2145. https://doi.org/10.1182/blood.2020004856

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458. https://doi.org/10.1038/bmt.2012.244

    Article  CAS  PubMed  Google Scholar 

  4. Maiti A, Konopleva MY (2022) How we incorporate venetoclax in treatment regimens for acute myeloid leukemia. Cancer J 28(1):2–13. https://doi.org/10.1097/PPO.0000000000000567

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Aiba M, Shigematsu A, Suzuki T, Miyagishima T (2023) Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia. Ann Hematol 102(3):541–546. https://doi.org/10.1007/s00277-023-05102-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose, Tokyo, 204-8588, Japan

    Yoshito Gando & Takeo Yasu

Authors
  1. Yoshito Gando
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takeo Yasu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takeo Yasu.

Ethics declarations

Ethics approval

The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board (or Ethics Committee) of the Meiji Pharmaceutical University (202239).

Consent to participate

Not applicable

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gando, Y., Yasu, T. Real-world treatment patterns of venetoclax and azacytidine therapy in Japanese patients with acute myeloid leukemia. Ann Hematol 102, 1283–1285 (2023). https://doi.org/10.1007/s00277-023-05201-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05201-w

Search

Navigation